Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma
- 1 September 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (25), 4162-4168
- https://doi.org/10.1200/jco.2008.21.3496
Abstract
Purpose: To evaluate the safety and efficacy of high-dose [131I]metaiodobenzylguanidine ([131I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL). Methods: Fifty patients with metastatic PHEO or PGL, age 10 to 64 years, were treated with [131I]MIBG doses ranging from 492 to 1,160 mCi (median, 12 mCi/kg). Cumulative [131I]MIBG administered ranged from 492 to 3,191 mCi. Autologous hematopoietic stem cells were collected and cryopreserved before treatment with [131I]MIBG greater than 12 mCi/kg or with a total dose greater than 500 mCi. Sixty-nine [131I]MIBG infusions were given, which included infusions to 35 patients treated once and infusions to 15 patients who received two or three treatments. Response was evaluated by [123I]MIBG scans, computed tomography/magnetic resonance imaging, urinary catecholamines/metanephrines, and chromogranin A. Results: The overall complete response (CR) plus partial response (PR) rate in 49 evaluable patients was 22%. Additionally, 35% of patients achieved a CR or PR in at least one measure of response without progressive disease, and 8% of patients maintained stable disease for greater than 12 months. Thirty-five percent of patients experienced progressive disease within 1 year after therapy. The estimated 5-year overall survival rate was 64%. Toxicities included grades 3 to 4 neutropenia (87%) and thrombocytopenia (83%). Grades 3 to 4 nonhematologic toxicity included acute respiratory distress syndrome (n = 2), bronchiolitis obliterans organizing pneumonia (n = 2), pulmonary embolism (n = 1), fever with neutropenia (n = 7), acute hypertension (n = 10), infection (n = 2), myelodysplastic syndrome (n = 2), and hypogonadism (n = 4). Conclusion: Although serious toxicity may occur, the survival and response rates achieved with high-dose [131I]MIBG suggest its utility in the management of selected patients with metastatic PHEO and PGL.Keywords
This publication has 20 references indexed in Scilit:
- Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazineCancer, 2008
- Pheochromocytoma: an update on genetics and managementEndocrine-Related Cancer, 2007
- Malignant Pheochromocytomas and ParagangliomasAnnals of the New York Academy of Sciences, 2006
- Malignant PheochromocytomaAnnals of the New York Academy of Sciences, 2006
- Tumor response and toxicity with multiple infusions of high dose 131I‐MIBG for refractory neuroblastomaPediatric Blood & Cancer, 2004
- Fatal form of phaeochromocytoma presenting as acute pyelonephritisEuropean Journal of Anaesthesiology, 2001
- Fatal form of phaeochromocytoma presenting as acute pyelonephritisEuropean Journal of Anaesthesiology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Phaeochromocytoma presenting as acute circulatory collapse and abdominal painIntensive Care Medicine, 1993
- Adult respiratory distress syndrome in a pregnant patient with a pheochromocytomaJournal of Surgical Oncology, 1985